- Home
- GLUE vs KRNY Comparison
GLUE vs KRNY Comparison
Compare GLUE & KRNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | KRNY |
|---|---|---|
| Founded | 2019 | 1884 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 504.9M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GLUE | KRNY |
|---|---|---|
| Price | $19.67 | $7.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $32.00 | $8.00 |
| AVG Volume (30 Days) | ★ 981.9K | 267.8K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 5.47% |
| EPS Growth | N/A | ★ 130.22 |
| EPS | N/A | ★ 0.30 |
| Revenue | ★ $123,672,000.00 | $2,580,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | $2.45 | $17.52 |
| P/E Ratio | $72.42 | ★ $26.80 |
| Revenue Growth | ★ 63.54 | 36.00 |
| 52 Week Low | $3.76 | $5.76 |
| 52 Week High | $25.77 | $8.50 |
Technical Indicators
Market Signals| Indicator | GLUE | KRNY |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 49.73 |
| Support Level | $17.36 | $7.77 |
| Resistance Level | $20.24 | $7.95 |
| Average True Range (ATR) | 1.05 | 0.18 |
| MACD | 0.33 | -0.01 |
| Stochastic Oscillator | 65.81 | 17.27 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About KRNY Kearny Financial Corp
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.